Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®Business Wire • 02/22/24
Why Ligand Pharmaceuticals (LGND) Dipped More Than Broader Market TodayZacks Investment Research • 02/21/24
Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024Business Wire • 02/13/24
Here's Why Ligand Pharmaceuticals (LGND) Fell More Than Broader MarketZacks Investment Research • 02/13/24
Iambic Therapeutics Announces New Research Published in Nature Machine Intelligence Demonstrating the Capabilities of Its Generative AI NeuralPLexer Technology to Predict Protein-Ligand Complex StructuresBusiness Wire • 02/12/24
Ligand Pharmaceuticals (LGND) Advances While Market Declines: Some Information for InvestorsZacks Investment Research • 02/06/24
Ligand Pharmaceuticals (LGND) Suffers a Larger Drop Than the General Market: Key InsightsZacks Investment Research • 01/12/24
U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum ContagiosumBusiness Wire • 01/05/24
Ligand Pharmaceuticals (LGND) Just Overtook the 200-Day Moving AverageZacks Investment Research • 12/14/23
Ligand (LGND) Posts Long-Term Outlook, Updates Portfolio ProgressZacks Investment Research • 12/13/23
Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 GuidanceBusiness Wire • 12/12/23
Ligand (LGND) Up 12.4% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/08/23
Ligand to Host Investor and Analyst Day on December 12, 2023 in New York CityBusiness Wire • 12/06/23
How Much Upside is Left in Ligand (LGND)? Wall Street Analysts Think 90.66%Zacks Investment Research • 11/22/23
5 Biotech Stocks Likely to Thrive as Industry Prospects Look BrightZacks Investment Research • 11/22/23